SEC Form 4 · accession 0001179110-18-004030
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Mar 9, 2018
Accepted (ET)
Mar 12, 2018 · 1:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2018 | S | 5,036 | $9.07 | D | 143,470 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 5,036 shares at a sale price per share of $9.07. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.